ConductScience.org, home

Comparison · NCT04076579-deaths

Cohort 1 vs Cohort 2: deaths from any cause

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Cohort 1 vs Cohort 2: deaths from any cause. Trial comparisons, record NCT04076579-deaths. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04076579-deaths

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.6250.3860.815wilson
Risk in group 20.3850.1770.645wilson
Risk difference, group 1 minus group 20.24-0.1130.522newcombe hybrid score
Risk ratio, group 1 over group 21.630.7413.56log
Odds ratio, group 1 over group 22.670.59112log
Number needed to harm, for one more death from any cause on Cohort 1 than on Cohort 24.16from the risk difference intervalthe interval includes no difference

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Cohort 1
Both cohorts received the same treatment:~* Cohort 1: Leiomyosarcoma and liposarcoma~* Cohort 2: Other bone or soft tissue sarcoma histologies Treatment consists of 21-day cycles for a maximum of 18 months. Olaparib: Olaparib taken by mouth twice daily Trabectedin: Trabectedin administered intravenously (IV) every 21 days
1016EG000
Group 2Cohort 2
Both cohorts received the same treatment:~* Cohort 1: Leiomyosarcoma and liposarcoma~* Cohort 2: Other bone or soft tissue sarcoma histologies Treatment consists of 21-day cycles for a maximum of 18 months. Olaparib: Olaparib taken by mouth twice daily Trabectedin: Trabectedin administered intravenously (IV) every 21 days
513EG001

Harm

What it counts
Total, all-cause mortality
Time frame
All adverse event data (serious and non-serious) collected from the time of the initial study treatment administration through 30 days after the last dose of study treatment; additionally, any serious adverse event occurring more than 30 days after the last study treatment if considered to be related to the study treatment. Data was collected during a 3 year period.

Source ClinicalTrials.gov

Trial

Title
Trabectedin in Combination With Olaparib in Advanced Unresectable or Metastatic Sarcoma
NCT number
NCT04076579
Phases
PHASE2
Conditions
Sarcoma, Sarcoma Metastatic
Interventions
Olaparib, Trabectedin
Lead sponsor
University of Michigan Rogel Cancer Center
Results first posted
2024-07-29

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT04076579-deaths